ArticleRheumatology (Oxford, England)2026
Incorporating frailty and disease severity into treatment decisions for older patients with ANCA-associated vasculitis.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOlder patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are underrepresented in clinical trials, and long-term outcome data in this group are limited. We evaluated treatment approaches and outcomes among hospitalized older patients with AAV.
methodsWe retrospectively collected clinical and laboratory data on all hospitalized patients aged 75 years or older who commenced remission induction with cyclophosphamide- or rituximab-based regimens for severe AAV between 2014 and 2021.
resultsEighty-four patients were included (median age 79, range 75-93), with a median follow-up of 21 months (interquartile range 12-44). Choice of induction regimen was influenced by age and frailty: the rituximab-cyclophosphamide combination was more commonly used in younger patients within the cohort, while low-dose rituximab was favoured for the oldest and most frail, including those requiring residential or nursing home care. The distribution of regimens was as follows: rituximab-cyclophosphamide combination (11.9%), cyclophosphamide (26.2%), standard-dose rituximab (39.6%) and low-dose rituximab (22.3%). Serious infection requiring hospital readmission occurred in 27% of patients within the first year, with rates of 37.5%, 23.8%, 25.8% and 31.6% across the respective treatment groups. One-year mortality was 20% overall (by treatment group: 10%, 23%, 14% and 26%). Increasing age was associated with higher mortality (hazard ratio [HR] 4.15; 95% CI: 1.62, 10.6), but not with serious infection (HR 1.18; 95% CI: 0.47, 2.93).
conclusionConsidering the enrichment for hospitalized patients with severe disease and advanced age, a mortality rate of 20% at 1 year that is comparable to less severe and younger cohorts suggests tailoring remission induction strategy according to a holistic assessment of frailty and disease activity may partially mitigate the higher risk of infection and mortality with advancing age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.